BEVACIZUMAB RELATED ADVERSE EVENTS IN PATIENTS AFFECTED BY METASTATIC COLORECTAL CANCER: A META-ANALYSIS

被引：0
|
作者：
Cinquini, Michela [1 ]
Galfrascoli, Elena [2 ]
Rossi, Antonio [3 ]
Manazza, Andrea [4 ]
Damia, Giovanna [5 ]
Banna, Giuseppe [6 ]
Tosoni, Alicia [7 ]
Tiseo, Marcello [8 ]
Farina, Gabriella
Garassino, Marina Chiara
机构：
[1] Mario Negri Inst Pharmacol Res, New Drug Dev Strategies Lab, Milan, Italy
[2] Hosp Pharm, Fatebenefratelli & Ophthalm Hosp, Milan, Italy
[3] SG Moscati Hosp, Avellino, Italy
[4] CeRMS, Mol Oncol Lab, Turin, Italy
[5] Mario Negri Inst Pharmacol Res, Mol Pharmacol Lab, Milan, Italy
[6] Vittorio Emanuele Hosp, Catania, Italy
[7] Maggiore Hosp, Bologna, Italy
[8] Maggiore Hosp, Parma, Italy
来源：
ANNALS OF ONCOLOGY | 2009年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [11] Usefulness of bevacizumab-induced hypertension in patients with metastatic colorectal cancer: an updated meta-analysis
    Zhang, Chun-Jing
    Zhang, Shu-Ying
    Zhang, Chun-Di
    Lin, Chun-Rong
    Li, Xue-Yan
    Li, Qiu-Yan
    Yu, Hai-Tao
    AGING-US, 2018, 10 (06): : 1424 - 1441
  • [12] The efficacy and safety of irinotecan± bevacizumab compared with oxaliplatin± bevacizumab for metastatic colorectal cancer A meta-analysis
    Dai, Jiali
    Chen, Yuetong
    Gong, Yang
    Wei, Jingsun
    Cui, Xiaowen
    Yu, Hualin
    Zhao, Wenjing
    Gu, Dongying
    Chen, Jinfei
    MEDICINE, 2019, 98 (39)
  • [13] Analysis of Adverse Events of Bevacizumab-containing Systemic Chemotherapy for Metastatic Colorectal Cancer in Japan
    Isobe, Taichi
    Uchino, Keita
    Makiyama, Chinatsu
    Ariyama, Hiroshi
    Arita, Shuji
    Tamura, Shingo
    Komoda, Masato
    Kusaba, Hitoshi
    Shirakawa, Tsuyoshi
    Esaki, Taito
    Mitsugi, Kenji
    Takaishi, Shigeo
    Akashi, Koichi
    Baba, Eishi
    ANTICANCER RESEARCH, 2014, 34 (04) : 2035 - 2040
  • [14] Effectiveness of bevacizumab in the treatment of metastatic colorectal cancer: a systematic review and meta-analysis
    Song, Yu
    Mao, Qianqian
    Zhou, Manling
    Liu, Cheng-Jiang
    Kong, Li
    Hu, Ting
    BMC GASTROENTEROLOGY, 2024, 24 (01)
  • [15] Effectiveness of bevacizumab in the treatment of metastatic colorectal cancer: a systematic review and meta-analysis
    Yu Song
    Qianqian Mao
    Manling Zhou
    Cheng-Jiang Liu
    Li Kong
    Ting Hu
    BMC Gastroenterology, 24
  • [16] A bibliometric analysis of immune-related adverse events in cancer patients and a meta-analysis of immune-related adverse events in patients with hepatocellular carcinoma
    Wang, Bengang
    Hao, Xiangjun
    Yan, Jinshan
    Li, Xin
    Zhao, Mingfang
    Han, Tao
    JOURNAL OF TRANSLATIONAL INTERNAL MEDICINE, 2024, 12 (03) : 225 - 243
  • [17] Adverse events of bevacizumab for triple negative breast cancer and HER-2 negative metastatic breast cancer: A meta-analysis
    Xun, Xueqiong
    Ai, Jun
    Feng, Fuhui
    Hong, Pan
    Rai, Saroj
    Liu, Ruikang
    Zhang, Baowen
    Zhou, Yeming
    Hu, Huiyong
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [18] Cardiovascular Adverse Events in Patients With Cancer Treated With Bevacizumab: A Meta-Analysis of More Than 20 000 Patients
    Totzeck, Matthias
    Mincu, Raluca Ileana
    Rassaf, Tienush
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2017, 6 (08):
  • [19] Bevacizumab in the treatment of metastatic colorectal cancer: Safety profile and management of adverse events
    Hurwitz, Herbert
    Saini, Shermini
    SEMINARS IN ONCOLOGY, 2006, 33 (05) : S26 - S34
  • [20] Risk of venous and arterial thromboembolic events in patients with metastatic breast cancer treated with bevacizumab: A meta-analysis
    Calvo, V.
    Ramirez, N.
    Saura, C.
    Vidal, M.
    Velasco, A.
    Llombart-Cussac, A.
    Cortes-Funes, H.
    Miles, D.
    Baselga, J.
    Cortes, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345